40th Annual J.P. Morgan Healthcare Conference Presentation
Repligen Snapshot
We are enabling efficient, single-use, flexible manufacturing of biological
drugs, providing first-to-market solutions for bioprocessing challenges
$660M
Revenue
2021e
(Midpoint 10/28/21
guidance)
Bioprocessing
solutions provider with
differentiated
technologies
R REPLIGEN
+45%*
5-year
CAGR
*+37% ex-COVID
Growing through
innovation,
acquisitions,
market strength
~38%
Revenue 2021e
from new markets
(COVID & GT)
~60% mAbs
Diversified customer
base, across all
biological drug
modalities
10
Disruptive
technologies
since 2014
Drives innovation, first-
to-market position,
market leadership;
accounts for ~25% of
our revenue in 2021
2021e figures above are based on 10/28/21 guidance
>$8B
TAM
New
applications
Capacity
expansion
~1,700
employees
Taking share in a
robust and expanding
global biologics
market
3View entire presentation